Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

2020401 citationsJournal Articlehybrid Open Access

Authors

Shugeng Gao · Chinese Academy of Medical Sciences & Peking Union Medical College

Ning Li · Chinese Academy of Medical Sciences & Peking Union Medical College

Shun‐Yu Gao · Chinese Academy of Medical Sciences & Peking Union Medical College

Qi Xue · Chinese Academy of Medical Sciences & Peking Union Medical College

Jianming Ying · Chinese Academy of Medical Sciences & Peking Union Medical College

Shuhang Wang · Chinese Academy of Medical Sciences & Peking Union Medical College

Abstract

Neoadjuvant sintilimab was tolerable for patients with NSCLC, and 40.5% MPR rate is encouraging. The decrease of maximum standardized uptake values after sintilimab might predict pathologic response.

Topics & Keywords

Colorectal and Anal Carcinomas Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Thoracic Oncology

Volume 15, Issue 5, pp. 816-826

DOI: 10.1016/j.jtho.2020.01.017

Field-Weighted Citation Impact: 60.22